Table 1 Patient background in all patients and by nintedanib starting doseage

(n = 111)

(n = 83)

(n = 28)

Age (years)

70 (66–75)

69 (66–74)

73 (66–78)

Male, n (%)

80 (72.1)

69 (83.1)

11 (39.3)

IPF/PF-ILD/SSc-ILD

59/35/17

44/28/11

15/7/6

Smoking (pack-years)

40 (20.0–57.6)

40 (22.0–64.0)

20 (6.3–47.5)

BMI (kg/m²)

22.9 (20.6–25.2)

23.2 (21.1–25.2)

21.7 (19.9–24.5)

BSA (m²)

1.62 (1.51–1.72)

1.64 (1.55–1.74)

1.48 (1.42–1.64)

Albumin (g/dL)

3.87 (3.59–4.10)

3.90 (3.60–4.10)

3.81 (3.50–4.18)

 C-reactive protein (mg/dL)

0.28 (0.10–0.59)

0.24 (0.10–0.67)

0.29 (0.13–0.52)

KL-6 (U/mL)

943 (633–1463)

953 (641–1334)

893 (617–1742)

White blood cell count (x10⁹/L)

7.400 (6.000–9.700)

7.400 (5.900–9.200)

7.300 (6.050–10.712)

Monocyte count (x10⁹/L)

0.451 (0.352–0.600)

0.466 (0.350–0.600)

0.409 (0.365–0.585)

mMRC score*

1.62 ± 1.05

1.47 ± 0.11

2.07 ± 0.19

FVC (L)

2.18 (1.61–2.86)

2.34 (1.78–2.92)

1.72 (1.38–2.52)

%FVC (%)

70.4 (57.1–87.4)

71.0 (59.7–87.4)

67.8 (55.8–88.2)

%DLco (%)

56.3 (44.8–73.7)

56.4 (46.0–72.5)

56.0 (44.1–77.5)

FVC decline per year (mL)

−125 (− 323–+20)

−150 (− 330–−20)

−20 (− 290–+100)

FVC decline per year (%)

−5.2 (− 15.2–+0.7)

−5.5 (− 14.9–−0.7)

−0.9 (− 17.0–+4.6)

%DLco decline per year (%)

−7.9 (− 13.0–−2.7)

−7.8 (− 11.8–−2.6)

−9.7 (− 18.1–−3.7)

Acute Ex, n (%)

11 (9.9)

10 (12.1)

1 (3.6)

Adverse events with medication change, n (%)

66 (59.5)

55 (66.3)

11 (39.3)